Eli Lilly and Company $LLY Shares Acquired by Stenger Family Office LLC

by · The Cerbat Gem

Stenger Family Office LLC lifted its stake in shares of Eli Lilly and Company (NYSE:LLY – Free Report) by 10.3% during the 1st quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm owned 6,375 shares of the company’s stock after acquiring an additional 595 shares during the period. Eli Lilly and Company accounts for approximately 1.1% of Stenger Family Office LLC’s portfolio, making the stock its 24th biggest position. Stenger Family Office LLC’s holdings in Eli Lilly and Company were worth $5,864,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also recently modified their holdings of LLY. Lmcg Investments LLC grew its holdings in shares of Eli Lilly and Company by 4.9% in the first quarter. Lmcg Investments LLC now owns 21,057 shares of the company’s stock valued at $19,368,000 after purchasing an additional 978 shares during the period. Penobscot Investment Management Company Inc. raised its stake in Eli Lilly and Company by 0.3% during the first quarter. Penobscot Investment Management Company Inc. now owns 12,057 shares of the company’s stock worth $11,090,000 after purchasing an additional 35 shares during the period. Richmond Investment Services LLC raised its stake in Eli Lilly and Company by 12.6% during the first quarter. Richmond Investment Services LLC now owns 1,429 shares of the company’s stock worth $1,314,000 after purchasing an additional 160 shares during the period. Warner Group LLC boosted its holdings in Eli Lilly and Company by 1.1% in the 1st quarter. Warner Group LLC now owns 1,935 shares of the company’s stock valued at $1,780,000 after purchasing an additional 21 shares during the last quarter. Finally, SilverOak Wealth Management LLC grew its stake in shares of Eli Lilly and Company by 5.3% in the 1st quarter. SilverOak Wealth Management LLC now owns 795 shares of the company’s stock valued at $731,000 after buying an additional 40 shares during the period. Institutional investors and hedge funds own 82.53% of the company’s stock.

Trending Headlines about Eli Lilly and Company

Here are the key news stories impacting Eli Lilly and Company this week:

  • Positive Sentiment: JPMorgan and RBC both raised their price targets on Eli Lilly, reinforcing Wall Street’s view that the company still has meaningful upside despite its rich valuation.
  • Positive Sentiment: LLY received another boost after its eczema treatment was approved in Canada, adding to the company’s growing non-obesity pipeline and supporting the bull case beyond weight-loss drugs. Article Title
  • Positive Sentiment: Several articles highlighted Eli Lilly’s strong GLP-1 and obesity momentum, noting record highs and ongoing investor enthusiasm around Mounjaro, Zepbound, and the broader obesity market.
  • Neutral Sentiment: Commentary pieces asked whether it is “too late” to buy LLY and whether the stock is too expensive, but these were largely opinion-driven and did not change the underlying business outlook.
  • Neutral Sentiment: Healthcare stocks were broadly weaker late in the day, which may have added some sector-level drag on LLY even as company-specific news remained constructive. Article Title
  • Negative Sentiment: Tampa General filed suit against Eli Lilly over pulled 340B discounts, creating a regulatory/legal overhang that could raise investor concerns about drug pricing and hospital reimbursement disputes. Article Title

Eli Lilly and Company Price Performance

Eli Lilly and Company stock opened at $1,218.76 on Thursday. The company’s 50 day simple moving average is $1,085.08 and its 200-day simple moving average is $1,031.42. The company has a debt-to-equity ratio of 1.26, a quick ratio of 1.10 and a current ratio of 1.50. Eli Lilly and Company has a 1 year low of $623.78 and a 1 year high of $1,249.45. The company has a market capitalization of $1.15 trillion, a price-to-earnings ratio of 43.30, a price-to-earnings-growth ratio of 1.54 and a beta of 0.51.

Eli Lilly and Company (NYSE:LLY – Get Free Report) last posted its quarterly earnings data on Thursday, April 30th. The company reported $8.55 earnings per share for the quarter, topping analysts’ consensus estimates of $6.97 by $1.58. Eli Lilly and Company had a net margin of 34.98% and a return on equity of 105.77%. The firm had revenue of $19.80 billion during the quarter, compared to analysts’ expectations of $17.82 billion. During the same quarter last year, the company posted $3.34 EPS. The firm’s quarterly revenue was up 55.5% on a year-over-year basis. Eli Lilly and Company has set its FY 2026 guidance at 35.500-37.000 EPS. As a group, equities research analysts expect that Eli Lilly and Company will post 35.7 earnings per share for the current year.

Eli Lilly and Company Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Thursday, September 10th. Stockholders of record on Friday, August 14th will be paid a $1.73 dividend. The ex-dividend date of this dividend is Friday, August 14th. This represents a $6.92 dividend on an annualized basis and a dividend yield of 0.6%. Eli Lilly and Company’s payout ratio is presently 24.58%.

Wall Street Analyst Weigh In

A number of analysts have recently issued reports on the stock. Wolfe Research restated an “outperform” rating and set a $1,350.00 price target on shares of Eli Lilly and Company in a report on Thursday, May 21st. Morgan Stanley upped their price objective on Eli Lilly and Company from $1,344.00 to $1,347.00 and gave the company an “overweight” rating in a report on Wednesday. Cantor Fitzgerald increased their price objective on Eli Lilly and Company from $1,230.00 to $1,350.00 and gave the stock an “overweight” rating in a research report on Monday. Sanford C. Bernstein reissued an “outperform” rating on shares of Eli Lilly and Company in a research note on Monday, June 8th. Finally, Guggenheim restated a “buy” rating and issued a $1,183.00 target price on shares of Eli Lilly and Company in a research report on Tuesday, May 5th. Two research analysts have rated the stock with a Strong Buy rating, twenty-three have given a Buy rating, four have given a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average price target of $1,255.89.

View Our Latest Report on LLY

About Eli Lilly and Company

(Free Report)

Eli Lilly and Company (NYSE: LLY) is a global pharmaceutical company founded in 1876 and headquartered in Indianapolis, Indiana. The company researches, develops, manufactures and commercializes a broad range of medicines and therapies for patients worldwide. Eli Lilly maintains operations and commercial presence across North America, Europe, Asia and other regions, serving both developed and emerging markets. The company has been led in recent years by President and Chief Executive Officer David A.

Further Reading

Want to see what other hedge funds are holding LLY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Eli Lilly and Company (NYSE:LLY – Free Report).